In the never-ending saga of CRISPR patents, the University of California has finally put some points on the board, with the U.S. Patent and Trademark Office granting it two genome-editing patents. One, granted on Tuesday, was first applied for in 2014. The other and more significant patent, applied for in 2015 but based on a 2012 discovery, will be granted next week.
The granted patent, number 9,994.831, covers “methods and compositions for modifying a single stranded target nucleic acid.” Next week’s, which is to be issued on June 19, covers the use of CRISPR-Cas9 for genome-editing in anything other than a bacterial cell and, specifically, where the targeted region on the genome is 10 to 15 nucleotides, or base pairs, long — the “letters” that constitute DNA and its cousin RNA. Next week’s patent is considered more foundational and therefore significant...
(There's more, but you have to go through a paywall to get it.) Source of above:
No comments:
Post a Comment